A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer
NCT01335269
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
96
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms
Interventions
DRUG:
BI 853520
Sponsor
Boehringer Ingelheim